Aishi announced that its original anti-epileptic drug, the anti-epileptic drug Varempanai (Weiketai ®), was accepted for the new drug market in China

Recently,, Aishi Announced that its original anti-epilepticdrug(http://(AED)http://
(AED)name: Fycompa ®; Chinese Product Name: ®) in China,New Drug(http://to be accepted in October 2018the drug is suitable for the use of partial seizures (accompanied or not accompanied by secondary full-blown seizures) patients 12 years of age and olderBased on the significant clinical benefits of the current treatment, the NationalMedicines(http://Supervisory Authority (NMPA) has granted the drug priority review eligibilityabout the Pyrumpanaian innovative anti-epileptic drug developed by the Tsukuba Institute, which is taken daily orallyThe drug is a highly selective, non-competitive AMPA receptor antagonist that reduces overexcitement in neurons associated with seizures by targeting the inhibition of glutamate activity in the synaptic after-membrane AMPA receptorOflampanay has been approved in more than 55 countries worldwide for the addition of partial seizures (accompanied or non-secondary full-blown seizures) in patients 12 years of age and olderIn addition, The total number of progenitors with epilepsy treated in more than 50 countries worldwide has been approved for the use of primary and comprehensive severe stoicsclerosis in patients aged 12 and overin the United States, Verlampane has been approved for single-drug and additional treatment for partial seizures (accompanied or non-secondary full-blown seizures) in patients 4 years and older